FDA Authorized AI Clairity has launched an FDA authorized AI platform for breast cancer risk prediction, enabling hospitals and radiology teams to deploy a trusted mammography based tool that aims to improve screening accuracy while reducing bias and overall care costs.

Executive Leadership Founder and CEO Connie Lehman has been appointed to lead Clairity, backed by recognition on TIME100 Health List, signaling credible leadership and strategic momentum that can help engage academic medical centers and health systems.

Market Traction The company is advancing with high visibility events and funding momentum, including participation in radiology and biotech conferences and a substantial Series B, underscoring traction with imaging networks and potential buyers seeking validated AI risk prediction solutions.

Strategic Fit The platform is designed to integrate with existing screening workflows and imaging IT ecosystems, highlighting a compelling fit for radiology departments and breast clinics seeking cost effective, accurate risk assessment within current PACS and EHR environments.

Expansion Potential International collaboration and multi center validation, along with ongoing RSNA and BIO exposure, position Clairity for global expansion through hospital networks, imaging centers, and partnerships with AI vendors or OEMs to scale deployment.